Citadel Advisors’s Exagen XGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.23M Buy
273,804
+259,411
+1,802% +$1.67M ﹤0.01% 6481
2026
Q2
$66.9K Sell
14,393
-216,722
-94% -$816K ﹤0.01% 12966
2026
Q1
$693K Buy
231,115
+42,657
+23% +$165K ﹤0.01% 8512
2025
Q4
$1.15M Buy
188,458
+72,228
+62% +$657K ﹤0.01% 7086
2025
Q3
$1.28M Buy
+116,230
New +$1.03M ﹤0.01% 7013
2025
Q2
– Sell
-4,284
Closed -$15.4K – 15396
2025
Q1
$15.4K Sell
4,284
-18,065
-81% -$68.2K ﹤0.01% 13322
2024
Q4
$91.6K Sell
22,349
-660
-3% -$2.38K ﹤0.01% 11609
2024
Q3
$71.1K Sell
23,009
-2,370
-9% -$6.14K ﹤0.01% 11537
2024
Q2
$46.2K Buy
25,379
+18,139
+251% +$30.7K ﹤0.01% 11852
2024
Q1
$11.5K Sell
7,240
-13,495
-65% -$26.2K ﹤0.01% 13406
2023
Q4
$41.3K Buy
+20,735
New +$35.9K ﹤0.01% 11985
2022
Q3
– Sell
-27,996
Closed -$156K – 13739
2022
Q2
$160K Buy
+27,996
New +$163K ﹤0.01% 10922

Other funds holding XGN

Citadel Advisors's XGN Position: Q3 2026 in Review

Citadel Advisors increased its Exagen (XGN) stake by 1,802% in Q3 2026, buying an estimated $1.67M and bringing the position to 273,804 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #6481.

Citadel Advisors first reported a position in XGN in Q2 2022 and has held it in 12 quarters since. 78 funds tracked by Wall St. Rank hold XGN as of Q3 2026.

  • Citadel Advisors held 273,804 shares of Exagen worth $2.23M as of Q3 2026.
  • Citadel Advisors bought 259,411 Exagen shares in Q3 2026, an estimated $1.67M.
  • Exagen made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #6481 holding.
  • Citadel Advisors first reported a position in Exagen in Q2 2022 and has held it in 12 quarters since.
  • 78 funds tracked by Wall St. Rank held Exagen as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.